NASDAQ:ALLO • US0197701065
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALLOGENE THERAPEUTICS INC (ALLO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-09 | Citizens | Upgrade | Market Perform -> Market Outperform |
| 2026-01-07 | UBS | Initiate | Buy |
| 2025-10-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2025-08-04 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2025-08-04 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-05-15 | Citigroup | Maintains | Buy -> Buy |
| 2025-05-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-05-14 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-03-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-14 | Citizens Capital Markets | Upgrade | Market Perform -> Market Outperform |
| 2025-03-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-03-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-09 | Truist Securities | Reiterate | Buy -> Buy |
| 2024-08-09 | Citigroup | Maintains | Buy -> Buy |
| 2024-08-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-31 | Piper Sandler | Initiate | Overweight |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 240K -99.38% | 95K -60.42% | 22K -76.84% | -100.00% | 18.544K | 26.152M 140,929.79% | 154.51M 490.82% | 346.98M 124.57% | 658.87M 89.89% | 916.69M 39.13% | 1.203B 31.23% | 1.468B 22.03% | |
| EBITDA YoY % growth | -321.15M -30.90% | -300.293M 6.49% | -243.843M 18.80% | -211.418M 20.21% | -211.348M -8.62% | -256.122M -21.19% | -290.639M -13.48% | -219.188M 24.58% | -63.668M 70.95% | N/A | N/A | N/A | |
| EBIT YoY % growth | -335.45M -31.14% | -314.492M 6.25% | -257.482M 18.13% | -225.094M 19.63% | -209.185M -1.09% | -221.304M -5.79% | -213.039M 3.73% | -21.571M 89.87% | 235.1M 1,189.89% | 405.03M 72.28% | 617.91M 52.56% | 808.51M 30.85% | |
| Operating Margin | -139,770.83% | -331,044.21% | -1,170,372.73% | N/A | -1,128,072.06% | -846.22% | -137.88% | -6.22% | 35.68% | 44.18% | 51.36% | 55.08% | |
| EPS YoY % growth | -2.32 -22.75% | -2.01 13.36% | -1.33 33.83% | -0.96 34.59% | -0.89 -2.17% | -0.82 7.57% | -0.72 12.26% | 0.09 112.27% | 1.36 1,441.75% | 2.21 61.97% | 3.29 48.96% | 4.39 33.33% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 30.33% | -0.20 13.15% | -0.21 -8.75% | -0.21 -26.25% | -0.19 0.65% | -0.19 5.53% | -0.18 13.61% | -0.23 -9.31% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | -43.784M 29.49% | -47.387M 1.75% | -50.91M -43.01% | -54.881M -82.66% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -46.976M 27.94% | -49.7M 8.70% | -52.64M -17.24% | -55.489M -30.86% | -51.538M -9.71% | -51.434M -3.49% | -51.897M 1.41% | -67.159M -21.03% |
All data in USD
21 analysts have analysed ALLO and the average price target is 7.57 USD. This implies a price increase of 240.84% is expected in the next year compared to the current price of 2.22.
ALLOGENE THERAPEUTICS INC (ALLO) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of ALLOGENE THERAPEUTICS INC (ALLO) is -0.2 USD and the consensus revenue estimate is 0 USD.